This Developmental Research Program (DRP) will promote the exploration of innovative ideas in translational cutaneous malignancy research through the funding of pilot projects proposed by Moffitt investigators;it will not support extensions of existing full projects. Dr. Vernon Sondak will lead the DRP. He has been a member of NCI Subcommittee G (training grants) and was the Principal Investigator of the first Pre-SPORE grant awarded by the State of Florida. He has mentored dozens of surgical oncologists and is known as an outstanding mentor. To maximize the likelihood that funded projects will be able to serve as replacement projects if needed, the DRP will support the establishment of new collaborations as well as facilitate either a talented investigator in another relevant field, i.e. a new investigator to cutaneous oncology, to become involved in cutaneous malignancy research or promote promising early research by an investigator already established in the cutaneous malignancy field. An innovative feature of the DRP is that investigators will be encouraged to propose projects that, while based at Moffitt, might involve a collaboration with an established Skin SPORE project at another Skin SPORE institution, or with the existing Moffitt Lung SPORE. In collaboration with the Moffitt Lung SPORE, up to one DRP award per year will be co-supported by the Skin SPORE as a cross-SPORE interaction. DRP projects that link to an ongoing Moffitt Skin SPORE project are encouraged. The DRP will provide guidance, advice, evaluation, and funding for up to three pilot projects per year. The goal for each pilot project is to generate sufficient high-quality data in the field of cutaneous malignancy prevention, treatment, basic research, or applied research to allow for submission of an independent project to the NIH or other federal agency for peer review funding. In addition, developmental projects could serve as potential replacement projects elevated to full project status if an existing full project is completed or fails to meet its translational goals and expectations as determined by the Skin SPORE External Advisory Board (EAB) in conjunction with the leadership of this Skin SPORE. The selection of DRP projects for funding by the Award Evaluation Committee (AEC) will be modeled after the NIH study section review process. The AEC will be chaired Dr. Vernon Sondak. Each pilot project will have three reviewers, a primary reviewer, a secondary reviewer, and a statistical reviewer. The three reviewers will be asked to assign priority scores from 1.0 to 9.0 to the project using the NIH scoring system. Projects from investigators new to cutaneous oncology will be given a high priority.

Public Health Relevance

The prior pilot award mechanism of the CMRC and the Pre-SPORE grant has been quite successful at promoting involvement in cutaneous oncology research among Moffitt investigators, resulting in 10 awards in the last 5 years, of which four led to peer reviewed funding, an excellent record. All four of the current Skin SPORE Projects started as CMRC/Pre-SPORE pilot proposals, which speaks to the success of this mechanism, and suggest that this DRP will positively impact on cutaneous oncology research at Moffitt.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Rebecca, Vito W; Wood, Elizabeth; Fedorenko, Inna V et al. (2014) Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics 13:1844-54
Kim, Sungjune; Ramakrishnan, Rupal; Lavilla-Alonso, Sergio et al. (2014) Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother 63:1009-21
Smyth, Tomoko; Paraiso, Kim H T; Hearn, Keisha et al. (2014) Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther 13:2793-804
Haarberg, H Eirik; Smalley, Keiran S M (2014) Resistance to Raf inhibition in cancer. Drug Discov Today Technol 11:27-32
Rebecca, Vito W; Smalley, Keiran S M (2014) Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol 91:417-25
Johnson, Douglas B; Smalley, Keiran S M; Sosman, Jeffrey A (2014) Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res 20:4186-92
Rebecca, Vito W; Alicea, Gretchen M; Paraiso, Kim H T et al. (2014) Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res 27:1154-8
Cheng, Fengdong; Lienlaf, Maritza; Perez-Villarroel, Patricio et al. (2014) Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol 60:44-53
Rebecca, Vito W; Massaro, Renato R; Fedorenko, Inna V et al. (2014) Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res 27:465-78
Fedorenko, Inna V; Fang, Bin; Koomen, John M et al. (2014) Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Res 24:448-53